Stock ACOR ACORDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Acorda Therapeutics, Inc. Nasdaq

Equities

ACOR

US00484M7002

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 03:35:15 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.73 USD -2.67% Intraday chart for Acorda Therapeutics, Inc. +92.11% -95.16%
Apr. 15 Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market MT
2023 Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023

Business Summary

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapies
100.0 %
104 87.6 % 118 100.0 % +13.28%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
119 100.0 % 118 100.0 % -0.79%

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,242,376 1,233,546 ( 99.29 %) 278 ( 0.0224 %) 99.29 %

Shareholders

NameEquities%Valuation
Davidson Kempner Capital Management LP
4.440 %
55,145 4.440 % 728 521 $
Renaissance Technologies LLC
3.684 %
45,761 3.684 % 604 549 $
Acadian Asset Management LLC
2.712 %
33,691 2.712 % 445 092 $
Vanguard Group, Inc. (Subfiler)
0.8701 %
10,808 0.8701 % 142 784 $
Ronald Cohen
0.6029 %
7,488 0.6029 % 98 924 $
Telemetry Investments LLC
0.5334 %
6,625 0.5334 % 87 523 $
BlackRock Institutional Trust Co. NA
0.5326 %
6,615 0.5326 % 87 391 $
Wells Fargo Bank NA
0.3012 %
3,741 0.3012 % 49 422 $
UBS AG (Investment Management)
0.1002 %
1,245 0.1002 % 16 448 $
Morgan Stanley Capital Services LLC
0.0947 %
1,176 0.0947 % 15 536 $

Company contact information

Acorda Therapeutics, Inc.

2 Blue Hill Plaza 3rd floor

10965, New York

+914 347 4300

http://www.acorda.com
address Acorda Therapeutics, Inc.(ACOR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ACOR.Q Stock
  4. ACOR Stock
  5. Company Acorda Therapeutics, Inc.